Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Andrea M. Perdue"'
Autor:
Sunny Jones, Paul C. Hendrie, Kelda M. Gardner, Mary-Elizabeth M. Percival, Roland B. Walter, Cody Hammer, Andrea M. Perdue, Kim Quach, Alicyn M. Davis, Bart L. Scott, Donelle Rizzuto, Pamela S. Becker, Frances Linzee Mabrey, Elihu H. Estey, Kathleen Shannon Dorcy, Frederick R. Appelbaum, Heather A. Smith
Publikováno v:
Blood advances. 4(4)
To improve patient quality of life and reduce health care costs, many conditions formerly thought to require inpatient care are now treated in the outpatient setting. Outpatient induction chemotherapy for acute myeloid leukemia (AML) may confer simil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41cde6c92458500c87bc0e1aa967b53f
https://pubmed.ncbi.nlm.nih.gov/32074276
https://pubmed.ncbi.nlm.nih.gov/32074276
Autor:
Heather A. Smith, Paul C. Hendrie, Kelda M. Gardner, Bart L. Scott, Roland B. Walter, Robert McCroskey, Weigang Tong, Elihu H. Estey, Mary-Elizabeth M. Percival, Pamela S. Becker, Andrea M. Perdue, Cody Hammer
Publikováno v:
Blood. 128:5207-5207
Introduction: Acute myeloid leukemia (AML) primarily affects older adults. Treating these patients requires balancing risk of toxicity with risk of ineffective therapy. Here we examine the ability of decitabine combined with cytarabine (DecitAC) to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05835335be3bf280db206a5690a58925
https://doi.org/10.1182/blood.v128.22.5207.5207
https://doi.org/10.1182/blood.v128.22.5207.5207
Autor:
Tara L. Chen, Megan Othus, Kaysey F. Orlowski, Heather A. Smith, Emily M Huebner, Paul C. Hendrie, Mary-Elizabeth M. Percival, Andrea M. Perdue, Roland B. Walter, Harry P. Erba, Anna B. Halpern, Bart L. Scott, Elihu H. Estey, Sarah A. Buckley, Pamela S. Becker
Publikováno v:
Blood. 128:1068-1068
Introduction:"7+3" with standard doses of cytarabine and an anthracycline has remained the mainstay of induction chemotherapy for newly diagnosed AML. Since some studies have shown improved outcomes with high-dose cytarabine, cladribine, or escalated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bc83eae422d6f6c3778e3c9a3ce7e1f
https://doi.org/10.1182/blood.v128.22.1068.1068
https://doi.org/10.1182/blood.v128.22.1068.1068
Autor:
Elihu H. Estey, Pamela S. Becker, Kaysey F. Orlowski, Heather A. Smith, Andrea M. Perdue, Tara L. Chen, Sarah A. Buckley, Anna B. Halpern, Bart L. Scott, Elizabeth M. Ranker, Paul C. Hendrie, Roland B. Walter, Megan Othus, Morgan A. Powell, Asma Anwar
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::593e6e2bf9d0c154eabca1e64d856873
https://doi.org/10.1016/j.clml.2015.07.027
https://doi.org/10.1016/j.clml.2015.07.027
Autor:
C. Anthony Blau, Jodie David, Elihu H. Estey, Sylvia Chien, Timothy J. Martins, Fabiana Ostronoff, Vivian G. Oehler, Andrea M. Perdue, Paul C. Hendrie, Pamela S. Becker
Publikováno v:
Blood. 124:3748-3748
Introduction. Resistance to therapy, rather than treatment-related mortality, is the usual cause of failure to cure AML. Typically all patients receive the same therapy despite great inter-patient variation in the mutations that underlie the disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4c50ad54913d223fd5502d2030b3e7e
https://doi.org/10.1182/blood.v124.21.3748.3748
https://doi.org/10.1182/blood.v124.21.3748.3748